Actively Recruiting
Percutaneous Cholangioscopic Treatment for Bile Duct Diseases Using the Spyglass System A Study for Patients Not Eligible for Endoscopic Treatment at Bologna University Hospital
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-02-10
24
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a percutaneous cholangioscopic assisted technique using the Spyglass mini-endoscopic system to treat bile duct diseases in participants who are not eligible for traditional endoscopic treatment. This study aims to determine whether this new approach can clear biliary stones and perform endobiliary biopsies more quickly than conventional methods. The study is a non-pharmacological, prospective, single-center interventional trial conducted at the Bologna University Hospital. Participants will undergo the percutaneous cholangioscopic-assisted treatment, which involves a preliminary puncture of the bile ducts followed by a cholangiographic study using the Spyglass system. This system provides direct viewing and allows guided lithotripsy or biopsy collection. Multiple treatment sessions may be scheduled every 15-20 days if residual stones remain, with percutaneous drainage left in place after each session to monitor complications and maintain access. During the study, participants will receive clinical laboratory monitoring and imaging tests as needed, with follow-up visits at 3, 6, 12, 24, and 36 months post-treatment. Researchers will collect clinical data and review anonymized imaging to evaluate outcomes such as number of treatments, duration of drainage, relapse-free interval, and length of hospitalization. The total study duration includes a 24-month enrollment phase followed by a 36-month follow-up period.
CONDITIONS
Brief Title
Diagnosis and Percutaneous Treatment of Biliary Tract Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Radiological diagnosis of indeterminate gallstones or bile duct stenosis not eligible for endoscopic treatment or with previous failed endoscopic treatment
- Good liver function with hemoglobin, hematocrit, GOT, GPT, and GGT within normal ranges
- Age over 18 years
- Signed informed consent obtained
You will not qualify if you...
- Presence of severe untreatable bleeding disorders
Research Team
A
Alberta Cappelli, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here